Clinical Trials Logo
  1. Home
  2. Other
  3. NCT05671900

Gemcitabine and Docetaxel Therapy in High-risk BCG-naive Patients With Non-muscle Invasive Bladder Cancer

Non-muscle-invasive Bladder Cancer Clinical Trial

Official title:
The Efficacy of Sequential Intravesical Gemcitabine and Docetaxel Therapy (GEM/DOCE) in High-risk BCG-naive Patients With Non-muscle Invasive Bladder Cancer (NMIBC)

Clinical Trial Summary

Bacillus Calmette-Guerin (BCG) is the standard of care for high-risk patients with non-muscle invasive bladder cancer (NMIBC) after transurethral tumor resection. Since 2012, global BCG shortage encouraged the search of alternative treatment for NMIBC treatment. Intravesical gemcitabine and docetaxel chemotherapy (GEM/DOCE) has shown safety and efficacy in 2 retrospective, single institution cohorts. At our institution, GEM/DOCE has been offered as an option for NMIBC in the treatment of high-risk BCG-naive patients per the protocol adapted from University of Iowa, in shortage situation. Our objective is to evaluate the efficacy of GEM/DOCE therapy.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05671900
Study type Interventional
Source Clinical Hospital Centre Zagreb
Contact
Status Active, not recruiting
Phase N/A
Start date April 1, 2020
Completion date December 2024
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05483868 - A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer Phase 1
Not yet recruiting NCT05547516 - Blue Laser -5ala Photodynamic Therapy (PDT) in High-Risk Non-muscle Invasive Bladder Cancer (NMIBC) Patients N/A
Not yet recruiting NCT05580354 - Safety and Efficacy of BCG Combined With Tislelizumab for BCG-untreated Patients With High-risk Non-muscle Invasive Bladder Cancer Phase 4
Recruiting NCT05519241 - A Phase I Intravesical PPM Therapy for NMIBC Phase 1
Not yet recruiting NCT05002556 - AFU Registry of the Therapeutic Management and Follow-up of Non-Muscle-Invasive Bladder Cancer
Recruiting NCT05544552 - Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations Phase 1/Phase 2
Recruiting NCT05796375 - Replacing Invasive Cystoscopy With Urine Testing for Non-muscle Invasive Bladder Cancer Surveillance N/A
Active, not recruiting NCT03528694 - Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer Phase 3
Recruiting NCT05790850 - Pre-Habilitation With Mindfulness and Exercise for Patients Undergoing Radical Cystectomy (PRIMER Trial) N/A
Completed NCT03664258 - A Multi-National Study In Bladder Cancer Patients to Detect Recurrences After TURB (Trans-urethral Resection of the Bladder) Earlier With the Xpert Bladder Cancer Monitor Assay (ANTICIPATE X)
Not yet recruiting NCT05962541 - Vesical Imaging-Reporting and Data System (VI-RADS) Followed by Photodynamic Trans-urethral Resection of Bladder Tumours (PDD-TURBT) to Avoid Secondary Resections (Re-TURBT) in Non-Muscle Invasive Bladder Cancers (NMIBCs) Phase 4
Active, not recruiting NCT05864599 - External Validation of Uromonitor as a Biomarker for Optimization of NMIBC Management by the CUETO Group
Not yet recruiting NCT03950362 - Bladder PREserVation by RadioTherapy and Immunotherapy in BCG Unresponsive Non-muscle Invasive Bladder Cancer Phase 2
Recruiting NCT05710848 - A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer Phase 1/Phase 2
Recruiting NCT05232136 - OH2 Oncolytic Viral Therapy in Non-Muscle-Invasive Bladder Cancer Phase 1/Phase 2
Recruiting NCT05825950 - Artificial Intelligence Prediction Tool in Non-muscle Invasive Bladder Cancer (NMIBC)
Recruiting NCT05626101 - Safety and Efficacy of Scheduled Intravesical Gemcitabine Versus Intravesical BCG for Intermediate and High Risk Non Muscle Invasive Bladder Cancer: A Prospective, Randomized Study N/A
Recruiting NCT05538663 - Intravesical BCG vs GEMDOCE in NMIBC Phase 3
Recruiting NCT06245759 - The Prognostic Impact of Tumor Location in Non-Muscle-Invasive Bladder Cancer Patients
Active, not recruiting NCT04690699 - LUMINOS-103: A Basket Trial Evaluating the Safety and Efficacy of Lerapolturev (PVSRIPO) and Lerapolturev in Combination With Anti-PD-1/L1 Checkpoint Inhibitors in Patients With Advanced Solid Tumors Phase 1/Phase 2